what’s in the works
CBX-12 is an alphalex conjugate that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12 was selected based on its ground-breaking efficacy and safety profile demonstrated in preclinical studies. CBX-12 has potential synergy with PD-1 inhibitors and other immuno-oncology drugs.
development focus: toxin conjugates
Highly potent anti-cancer agents that are unable to be administered as free drug are targeted to tumors with alphalex, creating novel agents that are effective across tumor types.
presentations & publications
Learn more about the science of alphalex and how it powers our work at Cybrexa.
669P: CBX-12-101: Final Results of a Phase 1 Study of CBX-12, a Peptide Drug Conjugate (PDC) in Patients (pts) with Advanced or Metastatic Solid Tumors.
Download
Victoria ADC Meeting
Download
Selection of Tubulin & Topl Inhibitor Payloads for Improved Tumor Specific Delivery by Peptide Drug Conjugate
Download
CBX-12-101: A First-in-Human Study of CBX-12, an Alphalex™ Peptide Drug Conjugate (PDC) in Patients with Advanced or Metastatic Solid Tumors
Download
Evaluation of antigen-agnostic anti-tumor activity and immunological memory induced by CBX-15 (alphalex™-MMAE) in the rat syngeneic breast cancer model
Download
TOP1-DNA trapping by exatecan and combination therapy with ATR inhibitor
Download
Antigen-independent tumor targeting by CBX-12 (alphalex™-exatecan) induces long-term antitumor immunity
Download
CBX-12-101: A first-in-human study of CBX-12, an alphalex™ peptide drug conjugate (PDC) in patients with advanced or metastatic solid tumors
Download
Development of an alphalex™-auristatin low pH targeting conjugate for the treatment of solid tumors
Download
Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity
Download
Development of alphalex™-auristatin low pH targeting conjugates for the treatment of solid tumors
Download
CBX-12 (alphalex™-exatecan) sensitizes tumors to immune checkpoint blockade in an antigen agnostic manner by immune activation
Download
Development of alphalex™-toxin low pH targeting conjugates for the treatment of solid tumors
Download
CBX-12: A low pH targeting alphalex™-exatecan conjugate for the treatment of solid tumors
Download
Targeting solid tumor acidic microenvironment with alphalex™ PARP inhibitor
Download
Development of tumor-targeted PARP inhibitors for the treatment of solid cancers
Download
MicroRNA silencing for cancer therapy targeted to the tumour microenvironment
Download